Administrative supplement to purchase a sequencing equipment

购买测序设备的行政补充 家长奖：R01GM098642 联合抗菌药物治疗的进化动力学 摘要 由于过度处方和滥用，抗生素因出现而失去效力。 以及抗药性细菌的迅速崛起。不同类型的抗生素，β-内酰胺类 自发现青霉素以来，已被开出用于治疗大多数感染的处方。 从那时起，细菌对β-内酰胺类抗生素的耐药性，由其产生的延长 产超广谱β-内酰胺酶(β-lacamase，ESBL)已成为一种普遍存在的酶。使用β-内酰胺酶 (血乳酸)抑制剂可以恢复β-内酰胺类药物对耐药细菌的疗效，这是一种策略 这对于在面临投资下降的情况下保护现有的抗生素是必要的 新的抗生素。然而，联合处理对β-内酰胺类药物选择的影响 抵抗并没有得到很好的理解。我们在家长奖中提出的研究将审查 这些深入的进化动力学使用数学建模和 定量实验。在这项行政补助金中，我们建议： 购买Illumina MiniSeq测序系统，该系统将用于促进 家长奖中提出的测量方法。

Administrative supplement to purchase sequencing equipment Parent award: R01GM098642 Evolutionary dynamics of combinational antimicrobial treatments Abstract Due to over-prescription and misuse, antibiotics are losing their efficacy due to emergence and rapid rise of antibiotic-resistant bacteria. Of different types of antibiotics, β-lactams have been prescribed to treat the majority of infections since the discovery of penicillin. Since then, bacterial resistance to β-lactams, mediated by the production of extended spectrum β-lactamase (ESBL) enzymes, has become widespread. Using β-lactamase (Bla) inhibitors can restore the efficacy of β-lactams against resistant bacteria, a strategy which is necessary to preserve existing antibiotics in the face of declining investment in new antibiotics. However, the effect of combination treatment on selection for β-lactam resistance is not well understood. Our proposed research in the parent award will examine these evolutionary dynamics in depth using a combination of mathematical modeling and quantitative experiments. In this Administrative Supplement grant, we propose to purchase an Illumina MiniSeq Sequencing System, which will be used to facilitate the measurements proposed in the parent award.